Zepp Health Corporation (ZEPP) reports Q4 2025 revenue of $85.2M, up 43% YoY, with strong growth in premium products and a positive outlook for 2026.

Key Takeaways

• Revenue for Q4 2025 reached $85.2 million, an increase of 43% year-over-year, meeting the upper end of guidance.
• Amazfit branded product sales grew 45.4% year-over-year in Q4, with a gross margin of 40.4%, the highest on record.
• The company anticipates Q1 2026 revenue between $50 million and $55 million, reflecting growth of 30% to 43% compared to the previous year.
• Net loss for Q4 2025 improved dramatically to $6.4 million, down from $22.5 million in Q4 2024.
• Total inventory decreased to $72.8 million, showcasing effective inventory management amid ongoing supply chain challenges.

Financial Performance

Zepp Health Corporation reported a robust performance in the fourth quarter and full year 2025, signaling a successful transition towards its hybrid training platform strategy. For Q4 2025, the company generated $85.2 million in revenue, marking a 43% increase compared to the same period last year. This growth is a significant recovery from the previous year, where revenue was $59.6 million. For the full year, total revenue reached $259 million, up 41.8% from $183 million in 2024.

The growth was driven by strong demand across various product lines, particularly in the Amazfit brand, which saw sales rise by 45.4% year-over-year in Q4. The gross margin for the quarter was 40.4%, reflecting an improvement of 3.6 percentage points from Q4 2024 and signaling effective pricing strategies and product mix enhancements.

Strategic Initiatives

Zepp Health's strategic focus on premium products and expansion into higher-value segments is evident in their recent product launches and partnerships. The company unveiled the Amazfit Active Max and Active 3 Premium models, targeting entry-level trainers and expanding their portfolio to meet diverse customer needs. Additionally, the T Rex Ultra 2, launched in February, represents the highest price point in the company’s history at $550. This commitment to premiumization reflects the company's strategy to enhance brand recognition and customer loyalty.

Moreover, Zepp Health is investing in marketing partnerships with elite athletes, such as Olympic medalist Josh Kerr. These partnerships not only serve as brand endorsements but also facilitate authentic user experiences that showcase the effectiveness of Zepp's technology in real-world training environments.

The company's collaboration with Tyrox, a rapidly growing endurance competition, further strengthens its market presence. By embedding its brand within the athlete experience, Zepp Health is generating organic visibility that transcends traditional marketing strategies.

Future Outlook

Looking ahead, management remains optimistic about the company’s trajectory. For Q1 2026, Zepp Health expects revenue between $50 million and $55 million, indicating year-over-year growth of 30% to 43%. This projection is grounded in strong sell-through trends and a solid order book, reinforcing the belief that current demand is structural rather than seasonal.

The company plans to continue optimizing its product mix and supply chain efficiency, which should further enhance margins. With a focus on premium offerings, Zepp Health's strategy aims to build upon its recent successes and drive sustainable growth.

Management also highlighted the importance of maintaining a disciplined approach to operating expenses. Despite an increase in total operating expenses, driven by strategic marketing investments and provisions for potential bad debts, the overall expense ratio improved as a percentage of sales. This reflects the company’s commitment to cost management while supporting growth initiatives.

Closing Assessment

Overall, Zepp Health Corporation's Q4 2025 earnings call illustrates a company well-positioned for continued growth. With strong revenue performance, an expanding premium product lineup, and strategic partnerships, Zepp Health is effectively navigating industry trends and consumer preferences. The company's focus on building a comprehensive ecosystem around its products through innovative software and community engagement further solidifies its competitive advantage. Investors can look forward to promising developments as Zepp Health enters 2026 with strong momentum and a clear vision for the future.

This analysis is based on public earnings call materials and is not investment advice.